Abstract
Human papilloma virus (HPV)-associated oropharyngeal carcinoma (HPV-OPC) is increasing in many countries. It has distinct microscopic and molecular features as well as clinical aspects. As for microscopic view, two subtypes, non-keratinizing squamous cell carcinoma (NKSCC) and hybrid SCC (HSCC), 3 variants of SCC, undifferentiated carcinoma (UC), basaloid carcinoma (BC), and papillary squamous cell carcinoma (PSCC), and 2 histological structures, abrupt keratinizarion and comedo-necrosis among non-maturing island are related with HPV-OPC. As for molecular aspects, HPV-OPC is more likely to have p53 degradation and Rb (retinoblastoma protein) inactivation with resulting p16 up-regulation compared to HPV-unassociated oropharyngeal carcinoma.
Keywords: Detection method, HPV-associated oropharyngeal carcinoma pathological diagnosis, Human papillomavirus (HPV), molecular diagnosis.
Current Cancer Therapy Reviews
Title:Pathology of the HPV-associated Oropharyngeal Carcinoma
Volume: 11 Issue: 1
Author(s): Yuki Fukumura
Affiliation:
Keywords: Detection method, HPV-associated oropharyngeal carcinoma pathological diagnosis, Human papillomavirus (HPV), molecular diagnosis.
Abstract: Human papilloma virus (HPV)-associated oropharyngeal carcinoma (HPV-OPC) is increasing in many countries. It has distinct microscopic and molecular features as well as clinical aspects. As for microscopic view, two subtypes, non-keratinizing squamous cell carcinoma (NKSCC) and hybrid SCC (HSCC), 3 variants of SCC, undifferentiated carcinoma (UC), basaloid carcinoma (BC), and papillary squamous cell carcinoma (PSCC), and 2 histological structures, abrupt keratinizarion and comedo-necrosis among non-maturing island are related with HPV-OPC. As for molecular aspects, HPV-OPC is more likely to have p53 degradation and Rb (retinoblastoma protein) inactivation with resulting p16 up-regulation compared to HPV-unassociated oropharyngeal carcinoma.
Export Options
About this article
Cite this article as:
Fukumura Yuki, Pathology of the HPV-associated Oropharyngeal Carcinoma, Current Cancer Therapy Reviews 2015; 11 (1) . https://dx.doi.org/10.2174/1573394711666150428003428
DOI https://dx.doi.org/10.2174/1573394711666150428003428 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Porphyrins and Phthalocyanines Decorated with Dendrimers: Synthesis and Biomedical Applications
Current Organic Synthesis Pathogenesis and Treatment of Secondary Hyperparathyroidism in Dialysis Patients: The Role of Paricalcitol
Current Vascular Pharmacology Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies
Current Cancer Drug Targets Role of Advanced Glycation End Products (AGEs) and Oxidative Stress in Diabetic Retinopathy
Current Pharmaceutical Design Anticancer Actions of Omega-3 Fatty Acids - Current State and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Molecular Mechanisms Underlying the Dedifferentiation Process of Isolated Hepatocytes and Their Cultures
Current Drug Metabolism Measurement of Cdk4 Kinase Activity Using an Affinity Peptide-Tagging Technology
Combinatorial Chemistry & High Throughput Screening Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design Integrase Interactor 1 in Health and Disease
Current Protein & Peptide Science Topoisomerase II Inhibitors and Poisons, and the Influence of Cell Cycle Checkpoints
Current Medicinal Chemistry Ras-Induced Senescence and its Physiological Relevance in Cancer
Current Cancer Drug Targets Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design [General Articles] Perspectives on Cancer Therapy: Cell Cycle Blockers and Perturbators
Current Medicinal Chemistry Anti-Vasopermeability Effects of PEDF in Retinal-Renal Disorders
Current Molecular Medicine The Induction and Repair of DNA Interstrand Crosslinks and Implications in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Abrogation of the G2 Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53-Deficient Tumor Cells to DNA-Damaging Agents
Current Clinical Pharmacology Targeting Nanomedicine to Brain Tumors: Latest Progress and Achievements
Current Pharmaceutical Design Microbubble-Assisted p53, RB, and p130 Gene Transfer in Combination with Radiation Therapy in Prostate Cancer
Current Gene Therapy Stem Cell Function, Self-Renewal, Heterogeneity, and Regenerative Potential in Skeletal Muscle Stem Cells
Recent Patents on Regenerative Medicine p16<sup>INK4</sup> as a Biomarker in Oropharyngeal Squamous Cell Carcinoma
Recent Patents on Biomarkers